Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations

Journal of Clinical Investigation

Volumn 104, Issue 6, 1999, Pages 697-708

  Goodyear, Carl S ^a,b   O'Hanlon, Graham M ^a   Plomp, Jaap J ^c   Wagner, Eric R ^a   Morrison, Ian ^a   Veitch, Jean ^a   Cochrane, Lynne ^a   Bullens, Roland W M ^c   Molenaar, Peter C ^c   Conner, Joe ^b   Willison, Hugh J ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT COMPONENT C3; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; CROSS REACTION; GASTROENTERITIS; GUILLAIN BARRE SYNDROME; IMMUNOHISTOLOGY; MOUSE; MUSCLE; NONHUMAN; PARALYSIS; PERIPHERAL NERVE; PRIORITY JOURNAL;

EID: 0032741980     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6837     Document Type: Article

References (44)

1. Hahn, A.F. 1998. Guillain-Barre syndrome. Lancet. 352:635-641.
2. Fisher, M. 1956. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Engl. J. Med. 225:57-65.
3. terBruggen, J.P., vanderMeche, F.G.A, deJager, A.E.J., and Polman, C.H. 1998. Ophthalmoplegic and lower cranial nerve variants merge into each other and into classical Guillain-Barre syndrome. Muscle Nerve. 21:239-242.
4. Rees, J.H., Soudain, S.E., Gregson, N.A., and Hughes, R.A.C. 1995. Campylobacter jejuni infection and Guillain Barré syndrome. N. Engl. J. Med. 333:1374-1379.
5. Chiba, A., Kusunoki, S., Shimuzu, T., and Kanazawa, I. 1992. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller-Fisher syndrome. Ann. Neurol. 31:677-679.
6. Willison, H.J., AlMemar, A., Veitch, J., and Thrush, D. 1994. Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides. Neurology. 44:2395-2398.
7. Ledeen, R.W., and Wu, G. 1992. Ganglioside function in the neuron. Trends Glycosci. Glycotech. 4:174-187.
8. Chiba, A., Kusunoki, S, Obata, H., Machinami, R., and Kanazawa, I. 1997. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 745:32-36.
9. Yuki, N., et al. 1993. A bacterium lipopolysaccharide that elicits Guillain Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178:1771-1775.
10. Aspinall, G.O., McDonald, A.G., Pang, H., Kurjanczyk, L.A., and Penner, J.L. 1994. Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain Barré syndrome. Biochemistry. 33:241-249.
11. Salloway, S., et al. 1996. Miller Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect. Immun. 64:2945-2949.
12. Yuki, N., et al. 1994. Molecular mimicry between GQ1b ganglioside and liposaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann. Neurol. 36:791-793.
13. Jacobs, B.C., et al. 1995. Serum anti-GQ1b antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann. Neurol. 37:260-264.
14. Hartung, H.-P., et al. 1996. Autoimmune responses in peripheral nerve. Springer Semin. Immunopathol. 18:97-123.
15. Roberts, M., Willison, H.J., Vincent, A., and Newsom-Davis, J. 1994. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet. 343:454-455.
16. Willison, H.J., et al. 1996. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J. Clin. Invest. 97:1155-1164.
17. Buchwald, B., Weishaupt, A., Toyka, K., and Dudel, J. 1998. Pre- and post-synaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur. J. Neurosci. 10:281-290.
18. Plomp, J.J., et al. 1999. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor endplates. Ann. Neurol. 45:189-199.
19. Aspinall, G.O., et al. 1993. Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipo-polysaccharides. Eur. J. Biochem. 213:1017-1027.
20. Aspinall, G.O., Lynch, C.M., Pang, H., Shaver, R.T., and Moran, A.P. 1995. Chemical structures of the core regions of Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide. Eur. J. Biochem. 213: 570-578.
21. Wirguin, I., et al. 1994. Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann. Neurol. 35:698-703.
22. Thompson, K.M., Hough, D.W., Maddison, P.J., Melamed, M.D., and Hughes-Jones, N. 1986. The efficient production of stable human monoclonal antibody-secreting hybridomas from EBV-transformed lymphocytes using the mouse myeloma A63-Ag8.653 as a fusion partner. J. Immunol. Methods. 94:7-12.
23. Paterson, G., Wilson, G., Kennedy, P.G.E., and Willison, H.J. 1995. Analysis of anti-GM1 antibodies cloned from motor neuropathy patients demonstrates diverse variable region gene usage with extensive somatic mutation. J. Immunol 155:3049-3059.
24. Kintner, C.R., and Brockes, J.P. 1985. Monoclonal antibodies to cells of a regenerating limb. J. Embryol. Exp. Morphol. 89:37-55.
25. O'Leary, C.P., et al. 1996. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J. Neurol. Neurosurg. Psychiatry. 61:649-652.
26. Yuki, N., et al. 1995. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN19) in three isolates from patients with Guillain Barre syndrome. J. Neurol. Sci. 130:112-116.
27. Jacobs, B.C., et al. 1997. Human IgM paraproteins demonstrate shared reactivity berween Campylobacter jejuni lipopolysaccharides and human peripheral nerve disialylated gangliosides. J. Neuroimmunol. 80:23-30.
28. Plomp, J.J., van Kempen, G.T.H., and Molenaar, P.C. 1992. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin-treated rats. J. Physiol. (Lond.) 458:487-499.
29. Rose, N.R. 1998. The role of infection in the pathogenesis of autoimmune disease. Semin. Immunol. 10:5-13.
30. Karlsen, A.E., and Dyrberg, T. 1998. Molecular mimicry between non-self, modified self and self in autoimmunity. Semin. Immunol. 10:25-34.
31. Wirguin, I., et al. 1997. Induction of anti-GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides. J. Neuroimmunol. 78:138-142.
32. Ritter, G., et al. 1996. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni. Int. J. Cancer. 66:184-190.
33. Fearon, D.T., and Locksley, R.M. 1996. The instructive role of innate immunity in the acquired immune response. Science. 272:50-53.
34. Lloyd, K.O., Gordon, C.M., Thampoe, I.J., and Dibenedetto, C. 1992. Cell-surface accessibility of individual gangliosides in malignant-melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res. 52:4948-4953.
35. Yuki, N., et al. 1995. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (Pen-19) in 3 isolates from patients with Guillain-Barre-syndrome. J. Neurol. Sci. 130:112-116.
36. Uncini, A., and Lugaresi, A. 1999. Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. Muscle Nerve. 22:640-644.
37. Dullforce, P., Sutton, D.C., and Heath, A.W. 1998. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat. Med. 4:88-91.
38. Willison, H.J., and Veitch, J. 1994. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol. 50:159-165.
39. Ebanks, R.O., and Isenman, D.E. 1996. Mouse complement component C4 is devoid of classical pathway CS convertase subunit activity. Mol. Immunol. 31:297-309.
40. Lazzeri, M., et al. 1998. Kidneys derived from mice transgenic for human complement blockers are protected in an in vivo model of hyperacute rejection. J. Urol. 159:1364-1369.
41. Hehmke, B., Schröder, D., Klöting, I., and Kohnert, K.D. 1991. Complement-dependent antibody-mediated cytotoxicity (C' AMC) to pancreatic islet cells in the spontaneously diabetic BB/OK rat: interference from cell-bound and soluble inhibitors. J Clin. Lab. Immunol. 35:71-81.
42. Hänsch, G.M., Hammer, C.H., Vanguri, P., and Shin, M.L. 1981. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc. Natl. Acad. Sci. USA. 78:5118-5121.
43. Shen, Y., Halperin, J.A., and Lee, C.M. 1995. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671:282-292.
44. Kusunoki, S., et al. 1996. Experimental sensory neuropathy induced by semitization with ganglioside GD1b. Ann. Neurol. 39:424-431.